BTK and B-cell chronic lymphocytic leukemia: As it is unclear whether the enzyme and receptor properties of CD38 have similar functional consequences, we also interrogated the outcomes of CD38 receptor inhibition by using a monoclonal CD38 blocking antibody (AT-1)15 administered to Th-CLL cell co-cultures (Figure 4A).